Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias ...Middle East

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura...

Read More Details
Finally We wish PressBee provided you with enough information of ( Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias )

Also on site :

• Term Sheet Next: How Facebook’s former chief revenue officer is coaching the next generation of startup founders
• Popular Dunkin’ Menu Item Gets a ‘Glow-Up’ in Limited-Edition Release
• Germany: Life imprisonment sentence for Syrian doctor Alaa Moussa